to complications including tophi (large deposits of urate crystals in joints and bone), urolithiasis (formation of stones in the bladder or urinary tract) and progression of chronic kidney disease (CKD). The associated pain, discomfort and potential lost days of work can result in increased morbidity and decreased quality of life, and it can place higher costs on the health care system. 1, 3 Recent observational studies suggest that patients' lack of knowledge about the disease and treatment options, combined with health care practitioners' lack of familiarity with clinical practice guidelines, represent significant barriers to optimal gout treatment. [4] [5] [6] In addition, most patients with gout are elderly and may have comorbidities, such as cardiovascular disease and/or renal impairment, which can further complicate treatment choices for both acute and chronic gout. 7, 8 High serum uric acid (SUA) levels increase the chance of monosodium urate crystallization and raise a patient's risk of gout flare. 1, 9, 10 The American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) guidelines provide recommendations for treating those with high serum uric acid (SUA) with urate-lowering therapy (ULT) to achieve a target SUA level of less than 360 µmol/L and less than 300 µmol/L for those with severe gout (ACR, based on consensus of experts; EULAR, based on descriptive or case studies). 1, 9, 11 Conversely, new guidelines from the American College of Physicians (ACP) encourage a treat-to-avoidsymptom strategy and avoid testing SUA levels altogether. They state that there are not enough data at this time to support the benefits of a treat-to-target strategy outweighing risks of increased monitoring and intensifying medication. 12 Additional clinical data are necessary to determine the most appropriate treatment strategy (i.e., treat to target vs treat to avoid symptoms), and currently, there is a discordance between guideline recommendations. In light of this uncertainty, patient and provider values, preferences and experience have more weight in the choice between treatment strategies. Regardless of the treatment strategy, pharmacists are able to collaborate in the optimization of gout management. A randomized controlled trial by Goldfien et al. 4 This practice tool is intended to provide guidance to pharmacists in assessing and managing both acute and chronic gout. The tool also provides a review of the management of drug-disease interactions associated with this population. The most recent guidelines from the ACR, ACP and EULAR for the management of gout were consulted. A literature search of Ovid MEDLINE, PubMed and International Pharmaceutical Abstracts was conducted from August to November 2016 to identify articles to review using various combinations of the following terms: gout, hyperuricemia, management, pharmacist, pharmacy, urate lowering therapy, colchicine and allopurinol. The authors also referred to the latest Canadian product monographs for colchicine, allopurinol and febuxostat for additional product information. Data were summarized in tables and organized alphabetically when no literature was available to support use of one class of medication over another.
Management of acute and chronic gout therapy
Case-Part I An obese 52-year-old man presents with an acute attack of a new diagnosis of gout. He has just come from the walk-in clinic with a prescription for indomethacin 50 mg orally as needed for pain. Medical history includes hypertension (average, 128/80 mmHg on treatment), type 2 diabetes and stage 3 chronic kidney disease (Cl Cr = 48 mL/min).
Anti-inflammatory medication should be initiated within 24 hours of symptom onset for acute gout attacks. There is no direct comparative evidence differentiating colchicine, corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs) as the preferred first-line option. Choice of therapy should be individualized based on severity, chronic gout management, comorbid conditions and concomitant medications and tailored based on response to treatment (Table 1) . 9, 11 Combination therapy with colchicine and NSAID or colchicine and corticosteroids may be considered in patients with severe pain and/or multiarticular involvement. 9 Chronic management of gout may include initiation of ULT with xanthine-oxidase inhibitors (i.e., allopurinol or febuxostat) in patients at high risk of complications or recurrent attacks (see Figure 1) . Discordance exists between guidelines in regards to starting ULT during an acute attack, due to lack of clear evidence pertaining to efficacy and safety. The EULAR and ACP guidelines give no clear recommendation; however, based on expert opinion, the ACR guidelines indicate that ULT can be started during an acute attack as long as the appropriate medication for the acute attack is being used. 1 Prophylaxis with low-dose NSAID or colchicine should be continued for 3 to 6 months, as initiation of ULT may increase risk of gout attack.
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Pharmacists should clarify the treatment strategy (i.e., treat to target vs empiric SUA lowering) with the patient and health care team. Along with initiation of acute gout medications, general lifestyle measures should be encouraged to manage modifiable gout risk factors and comorbidities (Table 2) . 1,9,11 Education on the causes of gout, common risk factors for gout and role of acute therapy and ULT medications may help promote patient adherence and facilitate shared decision making.
1,11,12

Special populations
A large proportion of patients with gout have a contraindication or comorbidity that warrants caution with at least one of the medications available for gout treatment. 7 Keenan et al. 7 found that approximately 50% of patients (n = 575) in their observational study had at least one contraindication to colchicine use. Despite this, more than 30% of these patients were prescribed colchicine. 7 Almost all drug-disease interactions with gout medications can be managed through dose adjustment or use of an alternate agent. 1, 9, 11 Populations most susceptible to adverse effects of gout medications include patients with CKD, heart failure (HF) and uncontrolled hypertension (Table 3) , where NSAIDs should be avoided. Elderly patients are potentially the most complicated to treat due to the increased incidence of renal dysfunction, cardiovascular comorbidities and risk of drug interactions. 8, 18 When making treatment decisions, individual risks must be weighed against the benefit of the medication to the patient, considering PRACTiCe TOOL comorbidities, medical history and concomitant medications.
1,11,18
Case-Part II An NSAID is not the most appropriate drug therapy considering the patient's history of hypertension and CKD. Medical history of diabetes suggests that corticosteroids would not be the first-line agent. You call the physician and suggest a low-dose colchicine regimen. You also provide your patient with education on gout and its management, as well as lifestyle measures to address his personal risk factors (e.g., obesity, hypertension and diabetes) (see Table 3 ). 
Chronic management
Allopurinol Initiate at 100 mg orally daily Increase by 100 mg/day every 2-5 weeks until achieved target SUA level less than 360 µmol/L (less than 300 µmol/L if tophi present)* -First-line ULT medication due to known safety, proven efficacy and low cost -Adverse effect: skin rash (1%-3%) Febuxostat 80 mg orally daily -Recommended if symptomatic gout and allergic to or unable to reach target SUA levels or desired symptom control with allopurinol -Third-party coverage may vary by insurer and by provincial drug plan *If using a treat-to-target strategy COX2, cyclooxygenase-2; GI, gastrointestinal; NSAID, nonsteroidal anti-inflammatory drug; SUA, serum uric acid; ULT, urate-lowering therapy.
PRACTiCe TOOL
Case-Part III
The patient returns twice in the next 6 months complaining of gout attacks. As your patient has frequent gout attacks and qualifies for ULT, you phone the physician and recommend initiation of allopurinol 100 mg daily.
Reassessing gout therapy
For patients on long-term ULT, there is insufficient evidence to recommend routine discontinuation for patients with infrequent or remote history of gout attacks on long-term allopurinol. 12 Consider discontinuation in patients below SUA target if using a treat-to-target strategy, asymptomatic for 5 years or in whom benefits no longer outweigh the risks of therapy.
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Suggestions for therapy reassessment are indicated in Table 4 . Gout is becoming the most common form of inflammatory arthritis in Canada.
2 Although a number of pharmacologic options exist for the acute and chronic management of the disease, FiguRe 1 Stepwise approach to management of gout CKD, chronic kidney disease; Cl Cr , creatinine clearance; NSAID, nonsteroidal anti-inflammatory drug; SCr, serum creatinine; SUA, serum uric acid; ULT, urate-lowering therapy. PRACTiCe TOOL considerations in terms of age, renal function, comorbidities and drug interactions complicate therapy. There is evidence that pharmacists can play a significant role in optimizing the care of this population. Through patient education and collaboration with prescribers, pharmacists may help to decrease the overall disease burden associated with gout. ■ Table 4 Gout therapy reassessment 1, 9, 11, 15 When to reassess? -Frequent gout attacks despite ongoing ULT -Long-term acute analgesic/anti-inflammatory medications with no ULT -Significant change to health status and/or comorbidities (e.g., recent MI, new diagnosis of diabetes or CKD)
PRACTiCe TOOL
What to look at? -Sua: Target less than 360 µmol/L (or less than 300 µmol/L if tophi present)* -SCr and Cl Cr : Determine level of renal function and need to dose adjust medications -Medication list: Review for potential drug interactions (e.g., CYP3A4
inhibitors and colchicine)
What to do? -If appropriate, initiate (or increase) ULT (see Table 1 ) -Measure SUA levels every 2-5 weeks during titration of ULT and every 6 months after target SUA is achieved or as often as practical *If using a treat-to-target strategy. CKD, chronic kidney disease; Cl Cr , creatinine clearance; MI, myocardial infarction; SCr, serum creatinine; SUA, serum uric acid; ULT, urate-lowering therapy.
